Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance

Melanoma Res. 2019 Jun;29(3):254-262. doi: 10.1097/CMR.0000000000000560.

Abstract

Long noncoding RNA X-inactive specific transcript (XIST) was confirmed to participate in the development of many cancers. However, the function of XIST in malignant melanoma (MM) remained largely unknown. In the current study, we found that the XIST expression level was upregulated in MM tissues and cell lines. In addition, the growth rate of MM cells transfected with silencing XIST was significantly decreased compared with that with silencing normal control. XIST knockdown inhibited proliferation and migration in MM cells and increased the oxaliplatin sensitivity of oxaliplatin-resistant MM cells. Bioinformatics analysis showed that XIST acts as a molecular sponge for miR-21 and miR-21 directly targets with 3'-UTR of PI3KR1. Furthermore, XIST knockdown inhibited PI3KRI and AKT expression, and promoted Bcl-2 and Bax expression. In short, the current study showed that XIST was a crucial regulator in progression and oxaliplatin resistance of MM, providing a novel insight into the pathogenesis and underlying therapeutic target for MM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Biomarkers, Tumor / genetics*
  • Cell Proliferation
  • Cohort Studies
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Melanoma / drug therapy
  • Melanoma / genetics
  • Melanoma / pathology*
  • Oxaliplatin / pharmacology*
  • Prognosis
  • RNA, Long Noncoding / genetics*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology*
  • Survival Rate
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • RNA, Long Noncoding
  • XIST non-coding RNA
  • Oxaliplatin